Extracellular vesicle diagnostics

Detecting cancer earlier through blood-based EV intelligence.

Vespera is building a liquid biopsy platform that captures and analyzes cancer-associated extracellular vesicles, starting with colorectal cancer and expanding toward pan-cancer detection and monitoring.

Vespera visual identity

Detect | Understand | Transform

The problem

Too many cancers are found after the window for simple intervention has narrowed.

Current screening pathways can be invasive, episodic, or limited by compliance. A scalable blood-based test could help identify risk earlier, support clinical decision-making, and enable longitudinal monitoring across cancer types.

Our solution

An EV-first platform for early cancer signals.

1. Capture

Isolate disease-relevant extracellular vesicles from blood, plasma, serum, or exosome-enriched samples without relying on magnetic bead workflows.

2. Detect

Read vesicle-associated signals with an optical and biomarker-driven assay designed for sensitivity, scalability, and clinical translation.

3. Expand

Begin with colorectal cancer as the wedge indication, then extend the platform to lung, pancreatic, breast, and broader pan-cancer applications.

Platform vision

From a colorectal cancer wedge to a pan-cancer diagnostics company.

Vespera is designed as a platform company, not a single-test project. The first clinical focus is colorectal cancer because it offers a clear unmet need, accessible clinical validation pathways, and a strong starting point for EV-based liquid biopsy development.

CRCFirst indication
EVsCore biology
Pan-cancerLong-term vision
The team

Built by founders at the intersection of optics, biotechnology, and clinical translation.

KK

Koray Kavaklı

Co-founder · Computational Optics & AI

PhD Candidate, Electrical & Electronics Engineering
Koç University
UA

Uğur Aygün, PhD

Co-founder · Biotechnology

Postdoctoral Researcher
Stanford School of Medicine

Building the next generation of EV-based cancer diagnostics.

Starting with colorectal cancer. Expanding toward all major cancers.

Contact the team